Enliven Therapeutics, Inc. (ELVN): Operating Cash Flow
-$70.30M
Year ended 2025-12-31
-$66.94M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$70.30M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$73.19M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$61.27M | n/m | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | -$32.08M | n/c | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | -$46.77M | n/m | 2023-02-10, From 2021-01-01 |
| 2020-12-31 | -$37.40M | n/m | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$21.88M | n/a | 2021-03-05, From 2019-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | -$70.30M | n/m |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | -$138.14M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$115.67M | n/m |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | -$88.21M | n/a |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$109.44M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$42.48M | n/m |
| Biohaven Ltd. (BHVN) | 2025-12-31 | -$609.44M | n/m |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | -$113.89M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | -$87.47M | n/m |
Compare ELVN, MPLT, RYTM, ORKA side by side · Screen every company in Pharmaceutical Preparations ↗